Loading company…
Reprogenix develops stem cell regenerative medicine and related products.
Founded in 2014, Reprogenix develops cell therapies and regenerative medicine products using platforms for stem cell lines, directed differentiation, gene editing and molecular and single-cell analysis. Its products include RGB5088 pancreatic islet cell injection. The company is based in Hangzhou, China. In November 2025, it raised CNY 500 million in Series A funding from returning investors Lotus Lake Capital and Beijia Investment Management, alongside China Reform Holdings, Fuzhe Capital, GAGE Capital, Orient Jiafu Asset Management, Sinowisdom, YuanBio Venture, Zhejiang Yuhang Industrial Transformation & Upgrading Investment, Yuansheng Venture Capital and other investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in